Implantable Devices in Iran: Clinical Evidence Requirements

1. Key takeaways

Implantable devices in Iran belong to the highest risk tier (Class D), and the review includes a complete clinical evaluation together with a risk-benefit analysis, with the possibility of a requirement for long-term safety evidence. The judgment of GRZAN is that the success or failure of an implantable device project depends on how the clinical evidence is organised, not on the quantity of evidence. The reviewer concentrates on three questions: whether the existing data can cover the Iranian population, whether the follow-up period is sufficient, and whether there is a continuous monitoring plan for long-term safety. These three questions must receive explicit answers inside the dossier, because a reviewer who has to construct the answers personally will construct doubts instead. Organising the dossier so that each question maps to a named chapter is the practical meaning of organising evidence rather than accumulating it. Answers that exist only implicitly do not count as answers in this review culture.

• Class C and Class D devices are required to provide stricter technical documentation together with clinical evaluation or clinical trial evidence.
• ISO 14155 (good clinical practice for medical device clinical trials), ISO 14971 (risk management) and ISO 10993 (biocompatibility) are internationally accepted standards generally accepted by Iran.
• Where a corresponding ISIRI standard exists, the ISIRI determination prevails.
• Population applicability must be argued proactively: the ethnicity, geography and baseline characteristics covered by the data, together with a justification of extrapolation.
• The follow-up plan is a document submitted before market entry and executed after market entry, supported by whatever interim data already exist.
• The risk-benefit analysis must state an explicit acceptability conclusion with supporting reasons, because the reviewer accepts an acceptable risk, not a risk-free device.
• Biocompatibility coverage under ISO 10993 is determined by contact duration and contact manner, and no applicable item should be deleted.
• Extrapolation arguments that are presented before the reviewer asks for them read as confidence, while the same arguments produced on request read as damage control.
• The three reviewer questions — population coverage, follow-up sufficiency, long-term monitoring — should each map to a named section of the dossier.

2. Legal basis

On the requirements for the high-risk classes: Class C and Class D devices must provide stricter technical documentation together with clinical evaluation or clinical trial evidence. This is documented in public industry material; the Iranian official document number has not been released through public channels, and this is a practical estimate.

On standards: ISO 14155 covering good clinical practice for medical device clinical trials, ISO 14971 covering risk management, and ISO 10993 covering biocompatibility are internationally accepted standards that Iran generally accepts. Where a corresponding ISIRI standard exists, the ISIRI determination prevails — this is a practical estimate. For implantable projects this means the standard set should be mapped against the ISIRI catalogue before the dossier is assembled.

The statutory anchor remains the Law Concerning Regulations of Medical, Laboratory, Pharmaceutical and Food and Beverage Affairs, recorded in FAOLEX as LEX-FAOC227692, dated 1955-06-20, Article 3.

3. Expert insights

Insight 1: population representativeness is the point that is questioned repeatedly. Whether clinical data generated outside Iran can be extrapolated to the Iranian population is the core question of the review. GRZAN recommends submitting a population applicability analysis proactively, stating the ethnicity, geography and baseline characteristics that the data cover, and providing the reasoned justification for the extrapolation, so that the reviewer encounters the argument before forming a doubt about it. The analysis also prevents the opposite error, which is over-claiming coverage that the data cannot support.

Insight 2: the follow-up plan is a document submitted before market entry and executed after market entry. Implantable devices require long-term follow-up data, but a registration stage cannot possibly hold complete long-term data. The feasible approach is to submit the follow-up protocol together with the corresponding commitments, and to explain the interim data that already exist. The combination of a credible protocol and honest interim data is what closes the long-term evidence gap at registration time. Interim data should be presented with their limitations stated plainly, because a credible account of what is not yet known strengthens, rather than weakens, the protocol commitment.

Insight 3: the risk-benefit analysis must respond frontally. The risks of implantable devices cannot be eliminated, and what the review accepts is a state of acceptable risk, not the absence of risk. The risk-benefit analysis in the dossier should therefore state its acceptability conclusion directly and list the supporting reasons, instead of leaving the reviewer to construct the conclusion from scattered material. A conclusion that arrives without stated reasons invites a deficiency request asking for exactly those reasons.

4. Practical recommendations

• Make the population applicability analysis a standalone chapter: state the data sources, the population characteristics and the justification for extrapolation.
• Submit the follow-up plan together with the interim data: address the long-term data gap through the combination of a protocol commitment plus the interim data that already exist, rather than as separate submissions.
• Give the risk-benefit analysis an explicit conclusion: judge the risk acceptable directly and list the reasons that support the judgment, so that the acceptability position is explicit on the page.
• Cover biocompatibility completely under ISO 10993: the contact duration and contact manner of an implantable device determine the evaluation items, and none of them should be deleted.

5. Verification checklist

• □ The Class D determination has been completed and the depth of review confirmed
• □ The clinical evaluation report includes the population applicability analysis and the extrapolation justification
• □ The follow-up plan and the existing interim data have been submitted together
• □ The risk-benefit analysis states an explicit acceptability conclusion with supporting reasons
• □ The ISO 10993 biocompatibility items fully cover the contact types and durations of the device

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team manages IFDA registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com